Ivermectine Cristers

Ivermectin, the active ingredient in Ivermectine Cristers, is an antiparasitic presented as an oral formulation for systemic use. It is prescribed to treat several helminthic and ectoparasitic infections in both adults and children, such as onchocerciasis, strongyloidiasis, scabies and lice infestations, under medical supervision.

GNH USA supplies Ivermectine Cristers as a licensed, EU‑origin, GDP‑compliant product to hospitals, pharmacies and clinics worldwide, supporting international procurement and distribution.

Ivermectine Cristers (ivermectin) acts on parasitic organisms, providing therapeutic benefit across a range of infections.

- Onchocerciasis: reduces microfilarial load and helps prevent ocular and skin disease. - Strongyloidiasis: eradicates intestinal larvae and lowers risk of hyperinfection syndrome. - Scabies: eliminates Sarcoptes scabiei mites, relieving itching and skin lesions. - Lice infestations: kills head and body lice, clearing infestations and preventing re‑colonisation.

Ivermectine Cristers may be associated with a range of adverse reactions. Patients should be monitored for any new symptoms during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: transient light‑headedness. - Pruritus: skin itching without rash. - Headache: mild tension‑type headache.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurologic toxicity: seizures or altered mental status. - Anaphylaxis: acute allergic reaction with respiratory compromise.

Before initiating therapy, clinicians should consider several safety aspects. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Breastfeeding: unknown excretion in milk; weigh maternal benefit against infant risk. - Hepatic impairment: dose adjustment may be required; monitor liver function. - Concomitant CNS depressants: may enhance sedation; observe for increased drowsiness. - Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Ivermectine Cristers can interact with other medicines; awareness of interaction severity helps guide monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise ivermectin plasma concentrations. - Co‑administration with other antiparasitics: increased risk of neurotoxicity. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Mild CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic levels. - P‑gp inhibitors (e.g., verapamil): modest increase in ivermectin exposure. - Other CNS depressants: may augment dizziness or somnolence. - Antihistamines: possible additive pruritus relief, monitor for excessive sedation.